Posted on January 16, 2013 by Andrew Eaton
GlaxoSmithKline researchers based in Stevenage, UK, and Upper Providence, PA, USA, have published a paper describing the miniaturisation and automation of the BlueScreen HC assay for use with 384 well plates.
The paper, to be published in Journal of Biomedical Screening, also describes the implementation of the assay for the assessment of genotoxic potential in parallel with, rather than subsequent to, the determination of activity at a therapeutic target.
“BlueScreen-384 was found to reduce the need for costly and time-consuming analogue testing using traditional genotoxicity tests, such as the Ames test.”
The BlueScreen-384 Assay as an Indicator of Genotoxic Hazard Potential in Early-Stage Drug Discovery.
Kate Simpson, Nicola Bevan, Paul Hastwell, Patrick Eidam, Poonam Shah, Elke Gogo, Steve Rees, Andrew Brown
High-throughput cell-based techniques that permit early detection of compound-induced genotoxic damage have recently become available. Methods based on induction of the GADD45a promoter are attractive because multiple intracellular mechanisms that detect genetic damage intersect at this checkpoint gene. Consequently, assays such as GreenScreen HC, which uses p53-competant human TK6 lymphoblastoid cells and a GADD45a-GFP reporter, have been developed. GreenScreen HC allows weekly testing of dozens of compounds using 96-well microplates, with high interassay consistency.
BlueScreen HC is a recent advancement, coupling GADD45a to Gaussia luciferase, with several advantages over GADD45a–GFP including the potential for miniaturization. Here we describe implementation of a 384-well BlueScreen assay. For drug discovery programs carrying out iterative analogue synthesis around a chemical lead series, these assays permit assessment of compound genotoxic potential in parallel to, rather than subsequent to, determination of activity at a therapeutic target. We demonstrate comparability of BlueScreen-384 to GreenScreen HC and illustrate the use of BlueScreen-384 to explore the structure-activity relationship around a genotoxic lead molecule to identify nongenotoxic analogues. BlueScreen-384 can reduce the need for costly and time-consuming analogue testing in more traditional genotoxicity tests, such as the Ames test.
- An e-publication (ahead of print) can be sourced from here.
- To find out more about how you can access BlueScreen, either in 384 well format or in the standard 96 well format, please contact your local Gentronix team
GlaxoSmithKline and the GSK logo are trade marks of the GlaxoSmithKline group of companies and are used with the permission of GlaxoSmithKline